newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics to Participate in Upcoming Investor Events

  • Tvardi Therapeutics (NASDAQ: TVRD) announced management participation in the Jefferies Global Healthcare Conference on June 4, 2026, featuring a fireside chat & 1-on-1 meetings in New York, NY.
  • Management will also attend the Raymond James BioPharma CEO Strategy Series on June 5, 2026, for a fireside chat with registration available online.
  • Webcasts for both events will be hosted on the Tvardi Investors' website with replays accessible for approximately 90 days post-conference.
  • Tvardi is developing novel oral small molecule therapies targeting STAT3 to treat inflammatory & proliferative diseases including hepatocellular carcinoma.
  • The company is currently conducting clinical trials with TTI-109 in healthy volunteers & TTI-101 in patients with hepatocellular carcinoma (NCT05440708).